Cequa (Cyclosporine 0.09%)

What Is Cequa and What Is It Used For?

Cequa (cyclosporine ophthalmic solution 0.09%) is a prescription eye drop used to increase tear production in patients with dry eye disease (keratoconjunctivitis sicca). It contains cyclosporine, a calcineurin inhibitor immunosuppressant, formulated with proprietary nanomicellar technology that enhances drug delivery to the ocular surface.

Dry eye disease is a multifactorial condition of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms. The disease affects an estimated 16 million adults in the United States alone, with global prevalence rates ranging from 5% to 50% depending on diagnostic criteria and population studied. Women, older adults, and individuals who spend extended periods looking at screens are disproportionately affected.

Cequa was approved by the United States Food and Drug Administration (FDA) in 2018 for the treatment of dry eye disease. It represents a significant advancement in cyclosporine-based ophthalmic therapy due to its unique nanomicellar formulation. This technology creates clear, aqueous solutions that form nanoscale micelles around the cyclosporine molecule, facilitating enhanced penetration through the aqueous tear film and into the ocular surface tissues where the drug exerts its therapeutic effect.

The active ingredient, cyclosporine, is a calcineurin inhibitor that works by partially suppressing the activation of T-lymphocytes on the ocular surface. In dry eye disease, chronic inflammation mediated by activated T-cells damages the lacrimal gland and conjunctival goblet cells, leading to reduced tear production and an unstable tear film. By interrupting this inflammatory cycle, cyclosporine allows the lacrimal functional unit to recover and resume more normal tear production.

Unlike artificial tears that provide only temporary symptom relief, Cequa addresses the underlying inflammatory mechanism of dry eye disease. Clinical trials have demonstrated that patients treated with Cequa showed statistically significant increases in Schirmer tear test scores compared to vehicle (placebo) at 12 weeks, indicating genuine improvement in tear production rather than mere symptomatic relief.

What Should You Know Before Taking Cequa?

Before using Cequa, inform your eye care provider about all medical conditions, current medications (especially other eye drops), contact lens use, and pregnancy or breastfeeding status. Cequa is for ophthalmic use only and should not be used if you have an active eye infection.

While Cequa is generally well tolerated, certain precautions must be observed to ensure safe and effective use. A thorough discussion with your healthcare provider about your complete medical history is essential before starting therapy. This includes disclosing any current or past ocular conditions, systemic diseases, and all medications you are taking, including over-the-counter products and dietary supplements.

Contraindications

Cequa is contraindicated in patients with known hypersensitivity to cyclosporine or any of the other ingredients in the formulation. Patients who have experienced allergic reactions to cyclosporine in any dosage form (oral, injectable, or other ophthalmic products) should not use Cequa. Signs of hypersensitivity may include severe eye redness, swelling of the eyelids or face, rash, or difficulty breathing.

Cequa should not be used in patients with active ocular infections including bacterial, viral (particularly herpes simplex keratitis), fungal, or parasitic infections of the eye. The immunosuppressive properties of cyclosporine could potentially worsen an existing infection by suppressing the local immune response needed to fight the pathogen. Any active eye infection should be treated and resolved before initiating Cequa therapy.

Warnings and Precautions

To avoid the risk of contamination, do not touch the tip of the single-dose container to the eye or any other surface. Each single-dose container is intended for immediate use in one or both eyes, and any remaining contents should be discarded immediately after application. Do not save unused portions for later use, as the preservative-free formulation has no antimicrobial protection once opened.

Patients with a history of herpes simplex keratitis should use Cequa with caution, even after the infection has resolved. Cyclosporine may potentially increase the risk of viral reactivation in susceptible individuals. Regular monitoring by an ophthalmologist is recommended in these patients. If signs of recurrent herpes simplex infection develop during Cequa use, the medication should be discontinued and appropriate antiviral treatment initiated.

The preservative-free single-dose containers of Cequa are specifically designed for ophthalmic use. The solution should never be ingested or injected. If accidentally swallowed, seek medical attention. Although systemic absorption from ophthalmic administration is minimal, the drug should still be used with appropriate caution.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Cequa in pregnant women. Systemic administration of cyclosporine has been shown to cause adverse reproductive effects in animal studies at doses significantly higher than the ophthalmic dose. However, the systemic exposure following ophthalmic administration of Cequa is extremely low (blood concentrations are typically below the limit of quantification). Pregnant women should discuss the potential risks and benefits with their healthcare provider before initiating or continuing Cequa therapy.

Cyclosporine is known to be excreted in human breast milk following systemic administration. It is not known whether clinically relevant levels of cyclosporine are present in breast milk after ophthalmic administration of Cequa. Given the minimal systemic absorption from eye drops, the risk to a nursing infant is expected to be low. Nevertheless, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.

How Does Cequa Interact with Other Drugs?

No formal drug interaction studies have been performed with Cequa. Due to its very low systemic absorption following ophthalmic use, systemic drug interactions are unlikely. However, if using multiple topical eye medications, a 15-minute interval between each product is recommended to prevent dilution and washout effects.

The pharmacokinetic profile of Cequa following ophthalmic administration results in negligible systemic exposure, making clinically significant systemic drug interactions extremely unlikely. Blood concentrations of cyclosporine after ophthalmic dosing are generally below the lower limit of quantification (0.1 ng/mL), which is far below the therapeutic range for systemic cyclosporine (100–400 ng/mL for organ transplant recipients). This substantial difference in systemic exposure means that the drug interaction profile of ophthalmic cyclosporine is fundamentally different from that of oral or intravenous cyclosporine.

While systemic interactions are negligible, local ocular interactions with other topical eye medications are a practical concern. When multiple ophthalmic products are used concurrently, improper timing of administration can lead to dilution, washout, or altered absorption of one or both medications. Maintaining an adequate interval between drops is essential for optimal therapeutic benefit from each product.

Patients with dry eye disease frequently use multiple ophthalmic products simultaneously, including artificial tears, anti-inflammatory agents, and medications for other coexisting eye conditions such as glaucoma. Coordinating the timing and sequence of these medications is an important aspect of managing complex ocular therapy regimens.

Major Interactions

There are no known major systemic drug interactions with Cequa when used as directed as an ophthalmic solution. This is a significant clinical advantage compared to systemic cyclosporine, which has a well-documented and extensive drug interaction profile involving CYP3A4 inhibitors and inducers, nephrotoxic drugs, and numerous other medication classes. The negligible systemic absorption of ophthalmic Cequa effectively eliminates these concerns.

Minor Interactions

The primary interaction considerations with Cequa involve local ocular interactions with other topical eye medications. Concurrent use of multiple eye drops without adequate spacing can reduce the effectiveness of each product through dilution and drainage. Patients should adhere to the recommended 15-minute interval between different eye drop products. If Cequa causes temporary blurred vision after application, patients should avoid driving or operating machinery until their vision clears.

What Is the Correct Dosage of Cequa?

The recommended dosage of Cequa is one drop in each eye twice daily (approximately 12 hours apart). Each single-dose container provides enough solution for one application in both eyes. Cequa is available in one strength: 0.9 mg/mL (0.09%).

Cequa is administered as a topical ophthalmic solution. The standardized dosing regimen is straightforward: one drop in each affected eye, twice daily, approximately 12 hours apart (typically once in the morning and once in the evening). Consistent adherence to this schedule is critical for achieving optimal therapeutic outcomes, as cyclosporine requires sustained tissue levels to effectively modulate the inflammatory process underlying dry eye disease.

Adults

To administer Cequa properly, wash your hands thoroughly before use. Invert the single-dose container a few times to obtain a uniform solution. Open the container by twisting off the tab. Tilt your head back slightly, pull down your lower eyelid to create a small pocket, and instill one drop into the pocket. Close your eye gently and press lightly on the inner corner of the eye (punctal occlusion) for 1–2 minutes. This technique reduces systemic absorption and maximizes the time the medication remains on the ocular surface.

Children

The safety and efficacy of Cequa have not been established in pediatric patients under the age of 18 years. Dry eye disease is uncommon in children but can occur in certain conditions such as Sjögren syndrome, Stevens-Johnson syndrome, graft-versus-host disease, or following certain surgical procedures. In these cases, the use of ophthalmic cyclosporine in children should be managed by a pediatric ophthalmologist who can weigh the potential benefits against the risks and monitor the patient closely.

Elderly

No dose adjustment is required for elderly patients. Dry eye disease is more prevalent in older adults, making this population a primary target for Cequa therapy. Clinical trials included patients up to 87 years of age, and no overall differences in safety or effectiveness were observed between elderly and younger adult patients. However, elderly patients may have more difficulty with the manual dexterity required to open single-dose containers and instill eye drops, and may benefit from assistance or instruction on proper technique.

Missed Dose

If you miss a dose of Cequa, apply it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not use a double dose to make up for a missed one. Consistent twice-daily dosing is important for maintaining steady-state drug levels on the ocular surface, but occasional missed doses are unlikely to significantly impact long-term treatment outcomes.

Overdose

Overdose by ophthalmic administration is unlikely due to the single-dose container design and the limited capacity of the eye to retain fluid (typically only about 7–10 microliters beyond the normal tear film volume). If too many drops are instilled, the excess will simply drain from the eye through the nasolacrimal duct or overflow onto the cheek. There are no reports of serious adverse events from ophthalmic overdose of cyclosporine. In the unlikely event of accidental ingestion, contact a poison control center. The small volume of a single-dose container is not expected to produce clinically significant systemic effects even if swallowed.

What Are the Side Effects of Cequa?

The most common side effects of Cequa are instillation site pain and conjunctival hyperemia (eye redness), occurring in approximately 22% and 6% of patients respectively. Most side effects are mild, localized to the eye, and temporary. Serious systemic side effects are very rare due to minimal absorption into the bloodstream.

Like all medications, Cequa can cause side effects, although not everybody experiences them. The side effect profile of Cequa has been characterized through pivotal clinical trials and post-marketing surveillance. Understanding the frequency, nature, and severity of potential side effects helps patients make informed decisions about their treatment and recognize when to seek medical attention.

The side effects of Cequa are predominantly ocular and localized to the application site. This is expected given the topical route of administration and the very low systemic absorption of the medication. The most frequently reported adverse reactions were identified in controlled clinical studies that compared Cequa to a vehicle (placebo) formulation, ensuring that only effects attributable to the active ingredient or the specific formulation were captured.

It is important to note that many of the common side effects, such as stinging and burning upon application, tend to diminish over time as the eyes become accustomed to the medication. Patients should be encouraged to continue therapy through the initial adjustment period unless side effects are severe or persistent, as discontinuing treatment prematurely may prevent them from experiencing the full therapeutic benefit of the drug.

How Should You Store Cequa?

Store Cequa at room temperature between 15°C and 25°C (59°F to 77°F). Keep the single-dose containers in their original foil pouch until ready to use. Protect from light. Discard any remaining solution immediately after use.

Proper storage of Cequa is essential to maintain the stability, sterility, and efficacy of the medication throughout its shelf life. The single-dose container format eliminates the need for preservatives but also means that once opened, the solution must be used immediately and any remaining contents discarded.

Store the foil pouches containing the single-dose containers at controlled room temperature, between 15°C and 25°C (59°F to 77°F). Brief excursions to temperatures between 2°C and 40°C are permissible during transport and handling, but prolonged exposure to extreme temperatures should be avoided. Do not freeze Cequa, and do not use it if the solution has been frozen. Do not store in direct sunlight or in excessively warm locations such as a car dashboard or near a heat source.

The single-dose containers should remain in their sealed foil pouch until the time of use to protect the medication from light degradation and environmental contamination. Each foil pouch typically contains multiple single-dose containers. Once a foil pouch is opened, the remaining single-dose containers within that pouch should be used within a reasonable timeframe as specified in the product labeling, typically within 30 days.

Keep Cequa out of the reach and sight of children. Do not use this medicine after the expiry date stated on the foil pouch and single-dose container. The expiry date refers to the last day of that month. Do not dispose of medications via wastewater or household waste; ask your pharmacist about proper disposal methods for medicines you no longer use.

What Does Cequa Contain?

Each milliliter of Cequa contains 0.9 mg of cyclosporine (0.09% w/v) as the active ingredient. The formulation uses a proprietary nanomicellar (NCELL) technology based on polyoxyl hydrogenated castor oil and octoxynol-40 to create a clear aqueous solution.

Cequa is formulated as a clear, colorless to slightly yellow, preservative-free ophthalmic solution. The absence of preservatives is particularly beneficial for dry eye patients, as preservatives such as benzalkonium chloride (BAK) found in many multi-dose eye drops are known to exacerbate ocular surface toxicity and dry eye symptoms with chronic use.

The active ingredient is cyclosporine at a concentration of 0.9 mg/mL (0.09% w/v). Cyclosporine is a cyclic polypeptide immunosuppressant originally isolated from the fungus Tolypocladium inflatum. Its molecular formula is C₆₂H₁₁₁N₁₁O₁₂, with a molecular weight of approximately 1202.6 daltons.

The inactive ingredients include: polyoxyl 40 hydrogenated castor oil (HCO-40), octoxynol-40, water for injection, and sodium hydroxide (to adjust pH). The HCO-40 and octoxynol-40 serve as the key surfactant components that form the nanomicellar structure, encapsulating the hydrophobic cyclosporine molecule within a clear aqueous medium. This nanomicellar architecture is central to the improved bioavailability of the formulation compared to emulsion-based cyclosporine products.

The solution has a pH adjusted to approximately 6.5 to 7.2, which is close to the natural pH of human tears (approximately 7.0 to 7.4), minimizing potential irritation upon instillation. The osmolality is formulated to be within a comfortable range for the ocular surface.

Frequently Asked Questions About Cequa